TY - JOUR
T1 - Tolerance induction by third-party "off-the-shelf" CD4 +CD25+ Treg cells
AU - Steiner, David
AU - Brunicki, Noga
AU - Blazar, Bruce R.
AU - Bachar-Lustig, Esther
AU - Reisner, Yair
PY - 2006/1
Y1 - 2006/1
N2 - Objective. Recent reports have shown that donor or host CD4 +CD25+ Treg cells can be used to control GVHD or graft rejection following allogeneic BMT in mice. In the present study we investigated the potential of third-party Treg cells compared to donor-type cells to facilitate BM allografting. Methods. Graft rejection is assessed in a mouse model of T cell-mediated BM allograft rejection. Lethally irradiated C3H mice are transplanted at day 2 after irradiation with T cell-depleted Balb/Nude BM. Graft rejection is induced by purified host-type T cells infused one day prior to BMT. Cells tested for their facilitating activity are added to the T cell-depleted BM allograft. Results. Naïve or ex vivo-expanded third-party Treg cells can effectively enhance engraftment of T cell-depleted BM allografts, exhibiting reactivity in vitro and in vivo similar to that found for donor-type Treg cells. Conclusion. The use of third-party Treg cells in contrast to donor-type cells could allow advanced preparation of a large bank of Treg cells (off-the-shelf), with all the appropriate quality controls required for cell therapy.
AB - Objective. Recent reports have shown that donor or host CD4 +CD25+ Treg cells can be used to control GVHD or graft rejection following allogeneic BMT in mice. In the present study we investigated the potential of third-party Treg cells compared to donor-type cells to facilitate BM allografting. Methods. Graft rejection is assessed in a mouse model of T cell-mediated BM allograft rejection. Lethally irradiated C3H mice are transplanted at day 2 after irradiation with T cell-depleted Balb/Nude BM. Graft rejection is induced by purified host-type T cells infused one day prior to BMT. Cells tested for their facilitating activity are added to the T cell-depleted BM allograft. Results. Naïve or ex vivo-expanded third-party Treg cells can effectively enhance engraftment of T cell-depleted BM allografts, exhibiting reactivity in vitro and in vivo similar to that found for donor-type Treg cells. Conclusion. The use of third-party Treg cells in contrast to donor-type cells could allow advanced preparation of a large bank of Treg cells (off-the-shelf), with all the appropriate quality controls required for cell therapy.
UR - http://www.scopus.com/inward/record.url?scp=30344450069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30344450069&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2005.10.011
DO - 10.1016/j.exphem.2005.10.011
M3 - Article
C2 - 16413392
AN - SCOPUS:30344450069
SN - 0301-472X
VL - 34
SP - 66
EP - 71
JO - Experimental Hematology
JF - Experimental Hematology
IS - 1
ER -